BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Czauderna F, Fechtner M, Aygün H, Arnold W, Klippel A, Giese K, Kaufmann J. Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res. 2003;31:670-682. [PMID: 12527776 DOI: 10.1093/nar/gkg141] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-hermelink H, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008;112:3403-11. [DOI: 10.1182/blood-2007-11-119362] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
2 Barbieri CE, Barton CE, Pietenpol JA. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 2003;278:51408-14. [PMID: 14555649 DOI: 10.1074/jbc.M309943200] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
3 Cain RJ, Ridley AJ. Phosphoinositide 3-kinases in cell migration. Biol Cell. 2009;101:13-29. [PMID: 19055486 DOI: 10.1042/bc20080079] [Cited by in Crossref: 165] [Cited by in F6Publishing: 98] [Article Influence: 12.7] [Reference Citation Analysis]
4 Shao S, Zhang W, Li X, Zhang Z, Yun D, Fu B, Zuo M. Reversal of MDR1 Gene-Dependent Multidrug Resistance in HL60/HT9 Cells Using Short Hairpin RNA Expression Vectors. Cancer Biotherapy and Radiopharmaceuticals 2010;25:171-7. [DOI: 10.1089/cbr.2008.0611] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst. 2006;98:545-556. [PMID: 16622124 DOI: 10.1093/jnci/djj133] [Cited by in Crossref: 280] [Cited by in F6Publishing: 247] [Article Influence: 17.5] [Reference Citation Analysis]
6 Liu X, Shi Y, Birnbaum MJ, Ye K, De Jong R, Oltersdorf T, Giranda VL, Luo Y. Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions. J Biol Chem 2006;281:31380-8. [PMID: 16923802 DOI: 10.1074/jbc.M606603200] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
7 Sundara Rajan S, Ludwig KR, Hall KL, Jones TL, Caplen NJ. Cancer biology functional genomics: From small RNAs to big dreams. Mol Carcinog 2020;59:1343-61. [PMID: 33043516 DOI: 10.1002/mc.23260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Noske A, Kaszubiak A, Weichert W, Sers C, Niesporek S, Koch I, Schaefer B, Sehouli J, Dietel M, Lage H, Denkert C. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: Increased expression of AKT in advanced ovarian cancer. Cancer Letters 2007;246:190-200. [DOI: 10.1016/j.canlet.2006.02.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
9 Santen RJ, Lobenhofer EK, Afshari CA, Bao Y, Song RX. Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat 2005;94:213-23. [PMID: 16258703 DOI: 10.1007/s10549-005-5776-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
10 Scherer L, Rossi JJ. Therapeutic applications of RNA interference: recent advances in siRNA design. Adv Genet 2004;52:1-21. [PMID: 15522731 DOI: 10.1016/S0065-2660(04)52001-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Roberts MS, Woods AJ, Dale TC, Van Der Sluijs P, Norman JC. Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol Cell Biol. 2004;24:1505-1515. [PMID: 14749368 DOI: 10.1128/mcb.24.4.1505-1515.2004] [Cited by in Crossref: 115] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
12 Manoharan M. RNA interference and chemically modified small interfering RNAs. Current Opinion in Chemical Biology 2004;8:570-9. [DOI: 10.1016/j.cbpa.2004.10.007] [Cited by in Crossref: 266] [Cited by in F6Publishing: 241] [Article Influence: 14.8] [Reference Citation Analysis]
13 Workman P. Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:499-515. [DOI: 10.1101/sqb.2005.70.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
14 Falasca M, Maffucci T. Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol 2014;5:391. [PMID: 25360116 DOI: 10.3389/fphys.2014.00391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, Leenders F, Arnold W, Giese K, Klippel A, Kaufmann J. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003;31:e127. [PMID: 14576327 DOI: 10.1093/nar/gng127] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 6.5] [Reference Citation Analysis]
16 Srinivas M, Singh Pathania A, Mahajan P, Verma PK, Chobe SS, Malik FA, Nargotra A, Vishwakarma RA, Sawant SD. Design and synthesis of 1,4-substituted 1H-1,2,3-triazolo-quinazolin-4(3H)-ones by Huisgen 1,3-dipolar cycloaddition with PI3Kγ isoform selective activity. Bioorganic & Medicinal Chemistry Letters 2018;28:1005-10. [DOI: 10.1016/j.bmcl.2018.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005;9:769-90. [PMID: 16083342 DOI: 10.1517/14728222.9.4.769] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
18 Yanagihara M, Katano M, Takahashi-sasaki N, Kimata K, Taira K, Andoh T. Ribozymes targeting serine/threonine kinase Akt1 sensitize cells to anticancer drugs. Cancer Science 2005;96:620-6. [DOI: 10.1111/j.1349-7006.2005.00088.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
19 López-Gambero AJ, Sanjuan C, Serrano-Castro PJ, Suárez J, Rodríguez de Fonseca F. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. Biomedicines 2020;8:E295. [PMID: 32825356 DOI: 10.3390/biomedicines8090295] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
20 Liu W, Wang G, Cao X, Luo X, Li Z, Deng Y, Li X, Wang S, Liu M, Hu J. Down-regulation of p110β expression increases chemosensitivity of colon cancer cell lines to oxaliplatin. J Huazhong Univ Sci Technolog Med Sci. 2012;32:280-286. [PMID: 22528234 DOI: 10.1007/s11596-012-0049-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kubo H, Hazeki K, Takasuga S, Hazeki O. Specific role for p85/p110beta in GTP-binding-protein-mediated activation of Akt. Biochem J 2005;392:607-14. [PMID: 16091017 DOI: 10.1042/BJ20050671] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
22 Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006;103:1289-94. [PMID: 16432180 DOI: 10.1073/pnas.0510772103] [Cited by in Crossref: 214] [Cited by in F6Publishing: 197] [Article Influence: 13.4] [Reference Citation Analysis]
23 Jang JY, Choi Y, Jeon YK, Kim CW. Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 2008;10:R11. [PMID: 18267033 DOI: 10.1186/bcr1857] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
24 Kumar A, Redondo-Muñoz J, Perez-García V, Cortes I, Chagoyen M, Carrera AC. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol Cell Biol 2011;31:2122-33. [PMID: 21383062 DOI: 10.1128/MCB.01313-10] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
25 Alladina SJ, Song JH, Davidge ST, Hao C, Easton AS. TRAIL-Induced Apoptosis in Human Vascular Endothelium Is Regulated by Phosphatidylinositol 3-Kinase/Akt through the Short Form of Cellular FLIP and Bcl-2. J Vasc Res 2005;42:337-47. [DOI: 10.1159/000086599] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
26 Li F, Pallan PS, Maier MA, Rajeev KG, Mathieu SL, Kreutz C, Fan Y, Sanghvi J, Micura R, Rozners E, Manoharan M, Egli M. Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme. Nucleic Acids Res 2007;35:6424-38. [PMID: 17881374 DOI: 10.1093/nar/gkm664] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
27 Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26. [PMID: 30782187 DOI: 10.1186/s12943-019-0954-x] [Cited by in Crossref: 294] [Cited by in F6Publishing: 297] [Article Influence: 98.0] [Reference Citation Analysis]
28 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
29 Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005;183:3-12. [DOI: 10.1111/j.1365-201x.2004.01382.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
30 Zhang M, Zhou Y, Zhang W, Zhang X, Pan Q, Ji X, Luo Z, Wu J. Apoptosis induced by short hairpin RNA-mediated STAT6 gene silencing in human colon cancer cells: . Chinese Medical Journal 2006;119:801-8. [DOI: 10.1097/00029330-200605020-00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Saunders IT, Mir H, Kapur N, Singh S. Emodin inhibits colon cancer by altering BCL-2 family proteins and cell survival pathways. Cancer Cell Int 2019;19:98. [PMID: 31011292 DOI: 10.1186/s12935-019-0820-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
32 Li C, Zhan Y, Ma X, Fang H, Gai X. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway. Clin Exp Med 2020;20:79-86. [PMID: 31664539 DOI: 10.1007/s10238-019-00590-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
33 Xie YE, Tang EJ, Zhang DR, Ren BX. Down-regulation of Bcl-XL by RNA interference suppresses cell growth and induces apoptosis in human esophageal cancer cells. World J Gastroenterol 2006; 12(46): 7472-7477 [PMID: 17167836 DOI: 10.3748/wjg.v12.i46.7472] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
34 Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A, Kaufmann J. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 2005;24:1138-49. [PMID: 15592522 DOI: 10.1038/sj.onc.1208236] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 5.5] [Reference Citation Analysis]
35 Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31:2705-2716. [PMID: 12771196 DOI: 10.1093/nar/gkg393] [Cited by in Crossref: 432] [Cited by in F6Publishing: 409] [Article Influence: 22.7] [Reference Citation Analysis]
36 Tondera D, Santel A, Schwarzer R, Dames S, Giese K, Klippel A, Kaufmann J. Knockdown of MTP18, a Novel Phosphatidylinositol 3-Kinase-dependent Protein, Affects Mitochondrial Morphology and Induces Apoptosis. Journal of Biological Chemistry 2004;279:31544-55. [DOI: 10.1074/jbc.m404704200] [Cited by in Crossref: 93] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
37 Sen G, Wehrman TS, Myers JW, Blau HM. Restriction enzyme–generated siRNA (REGS) vectors and libraries. Nat Genet 2004;36:183-9. [DOI: 10.1038/ng1288] [Cited by in Crossref: 112] [Cited by in F6Publishing: 98] [Article Influence: 6.2] [Reference Citation Analysis]
38 Milhavet O, Gary DS, Mattson MP. RNA Interference in Biology and Medicine. Pharmacol Rev 2003;55:629-48. [DOI: 10.1124/pr.55.4.1] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 4.4] [Reference Citation Analysis]
39 Chau NM, Ashcroft M. Akt2: a role in breast cancer metastasis. Breast Cancer Res 2004;6:55-7. [PMID: 14680486 DOI: 10.1186/bcr739] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
40 Gaben AM, Sabbah M, Redeuilh G, Bedin M, Mester J. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer 2012;12:291. [PMID: 22799881 DOI: 10.1186/1471-2407-12-291] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
41 Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends in Biochemical Sciences 2005;30:194-204. [DOI: 10.1016/j.tibs.2005.02.008] [Cited by in Crossref: 326] [Cited by in F6Publishing: 320] [Article Influence: 19.2] [Reference Citation Analysis]
42 Wang S, Basson MD. Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion. Exp Cell Res 2008;314:286-96. [PMID: 17825284 DOI: 10.1016/j.yexcr.2007.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
43 Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 2007;13:4051-60. [PMID: 17634529 DOI: 10.1158/1078-0432.CCR-06-3032] [Cited by in Crossref: 64] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
44 Héron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings BA, Fernandez A, Lamb NJ. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 2006;26:8267-80. [PMID: 16982699 DOI: 10.1128/MCB.00201-06] [Cited by in Crossref: 124] [Cited by in F6Publishing: 76] [Article Influence: 7.8] [Reference Citation Analysis]
45 Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20:539-50. [PMID: 16307918 DOI: 10.1016/j.molcel.2005.10.033] [Cited by in Crossref: 307] [Cited by in F6Publishing: 281] [Article Influence: 19.2] [Reference Citation Analysis]
46 Vogt PK, Bader AG, Kang S. Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology 2006;344:131-8. [PMID: 16364744 DOI: 10.1016/j.virol.2005.09.027] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
47 Amiri M, Hollenbeck PJ. Mitochondrial biogenesis in the axons of vertebrate peripheral neurons. Dev Neurobiol 2008;68:1348-61. [PMID: 18666204 DOI: 10.1002/dneu.20668] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 7.2] [Reference Citation Analysis]
48 Congmin G, Mu Z, Yihui M, Hanliang L. Survivin--an attractive target for RNAi in non-Hodgkin's lymphoma, Daudi cell line as a model. Leuk Lymphoma 2006;47:1941-8. [PMID: 17065009 DOI: 10.1080/10428190600725354] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
49 Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene silencing of β-catenin inhibits growth of human colon cancer cells. World J Gastroenterol 2007; 13(48): 6581-6587 [PMID: 18161931 DOI: 10.3748/wjg.v13.i48.6581] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
50 Tondera D, Czauderna F, Paulick K, Schwarzer R, Kaufmann J, Santel A. The mitochondrial protein MTP18 contributes to mitochondrial fission in mammalian cells. Journal of Cell Science 2005;118:3049-59. [DOI: 10.1242/jcs.02415] [Cited by in Crossref: 153] [Cited by in F6Publishing: 146] [Article Influence: 9.0] [Reference Citation Analysis]
51 Valdes-Gonzalez R, Dorantes LM, Bracho-Blanchet E, Rodríguez-Ventura A, White DJ. No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation. J Med Virol. 2010;82:331-334. [PMID: 20029803 DOI: 10.1002/jmv.21655] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
52 Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol Ther 2012;20:483-512. [PMID: 22186795 DOI: 10.1038/mt.2011.263] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 15.6] [Reference Citation Analysis]
53 Boutla A, Delidakis C, Livadaras I, Tabler M. Variations of the 3′ Protruding Ends in Synthetic Short Interfering RNA (siRNA) Tested by Microinjection in Drosophila Embryos. Oligonucleotides 2003;13:295-301. [DOI: 10.1089/154545703322616970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
54 Mikhailova M, Wang Y, Bedolla R, Lu XH, Kreisberg JI, Ghosh PM. AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. Adv Exp Med Biol 2008;617:397-405. [PMID: 18497063 DOI: 10.1007/978-0-387-69080-3_38] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
55 Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009;69:3955-3962. [PMID: 19366795 DOI: 10.1158/0008-5472.CAN-08-4450] [Cited by in Crossref: 161] [Cited by in F6Publishing: 78] [Article Influence: 12.4] [Reference Citation Analysis]
56 Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-9. [PMID: 16697955 DOI: 10.1016/j.ccr.2006.03.029] [Cited by in Crossref: 450] [Cited by in F6Publishing: 403] [Article Influence: 28.1] [Reference Citation Analysis]
57 Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31:2705-2716. [PMID: 12771196 DOI: 10.1093/nar/gng066] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
58 Leenders F, Möpert K, Schmiedeknecht A, Santel A, Czauderna F, Aleku M, Penschuck S, Dames S, Sternberger M, Röhl T, Wellmann A, Arnold W, Giese K, Kaufmann J, Klippel A. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 2004;23:3303-13. [PMID: 15282551 DOI: 10.1038/sj.emboj.7600345] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 3.7] [Reference Citation Analysis]
59 Attoub S, Arafat K, Kamel Hammadi N, Mester J, Gaben AM. Akt2 knock-down reveals its contribution to human lung cancer cell proliferation, growth, motility, invasion and endothelial cell tube formation. Sci Rep 2015;5:12759. [PMID: 26234648 DOI: 10.1038/srep12759] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
60 Lage H. Potential applications of RNA interference technology in the treatment of cancer. Future Oncology 2005;1:103-13. [DOI: 10.1517/14796694.1.1.103] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
61 Marqués M, Kumar A, Cortés I, Gonzalez-García A, Hernández C, Moreno-Ortiz MC, Carrera AC. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol. 2008;28:2803-2814. [PMID: 18285463 DOI: 10.1128/MCB.01786-07] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
62 Gaben AM, Saucier C, Bedin M, Redeuilh G, Mester J. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase. Mol Endocrinol 2004;18:2700-13. [PMID: 15297603 DOI: 10.1210/me.2003-0133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
63 Pu P, Kang C, Zhang Z, Liu X, Jiang H. Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Technol Cancer Res Treat 2006;5:271-80. [PMID: 16700623 DOI: 10.1177/153303460600500308] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
64 Watkins AM, Wuo MG, Arora PS. Protein-Protein Interactions Mediated by Helical Tertiary Structure Motifs. J Am Chem Soc 2015;137:11622-30. [PMID: 26302018 DOI: 10.1021/jacs.5b05527] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
65 Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol. 2007;13:6581-6587. [PMID: 18161931 DOI: 10.3748/wjg.13.6581] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
66 Vaish N, Agarwal P. The design, selection, and evaluation of highly specific and functional siRNA incorporating unlocked nucleobase analogs. Methods Mol Biol 2013;942:111-34. [PMID: 23027048 DOI: 10.1007/978-1-62703-119-6_6] [Reference Citation Analysis]